Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.

The British journal of dermatology - 18 Aug 2025

Wang Yi, Xu Guangchao, Xia Hongwei

Abstract excerpt

Mutant NRAS is the second-most common type of mutation in melanoma. The prognosis in patients with NRAS mutant melanoma is poor, and effective targeted treatment strategies are still lacking. Mutant NRAS mainly acts by activating RAF-MEK-ERK signalling to promote carcinogenesis in melanoma. In recent years, significant clinical advances have been made in targeting the NRAS-MAPK (mitogen-activated protein kinase)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Skin Neoplasms

Source

Identifiers

PMID: 40341941
DOI: 10.1093/bjd/ljaf178

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.PMID 40341941Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

MEK inhibitors for the treatment of NRAS mutant melanoma.Semantic proximity Read ↗

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read ↗

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.Semantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.Semantic proximity Read ↗

Insights into RAS-driven melanoma and its therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.